Cargando…

Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma.

Surgical biopsy specimens of 179 breast carcinoma were studied by steroid-binding and immunohistochemical assays or oestrogen and progesterone receptors (ER, PR) in order to explore reasons for discordant results between the two assay types. Receptor statuses in 18% of ER assays and 30% of PR assays...

Descripción completa

Detalles Bibliográficos
Autores principales: Helin, H., Isola, J., Helle, M., Koivula, T.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971742/
https://www.ncbi.nlm.nih.gov/pubmed/2202418
_version_ 1782134976029917184
author Helin, H.
Isola, J.
Helle, M.
Koivula, T.
author_facet Helin, H.
Isola, J.
Helle, M.
Koivula, T.
author_sort Helin, H.
collection PubMed
description Surgical biopsy specimens of 179 breast carcinoma were studied by steroid-binding and immunohistochemical assays or oestrogen and progesterone receptors (ER, PR) in order to explore reasons for discordant results between the two assay types. Receptor statuses in 18% of ER assays and 30% of PR assays were in disagreement. Immunohistochemistry-positive steroid-binding-negative status predominated among the discordant ER assays, while the discordant PR assays displayed the opposite situation. In discordant assays receptor concentration was significantly more often close to the cut-off (10-50 fmol mg-1) than in the concordant ones. Low binding affinity (high Kd) was also significantly associated with disagreeing assay results. These observations clearly indicate that immunohistochemical ER and PR assays measure high-affinity binding components (i.e. type I receptors) in steroid-binding assays. ER but not PR assays in premenopausal women disagreed more often than those in post-menopausal women. Such factors as histological type, specimen size in steroid-binding assay, grade of malignancy and tumour necrosis were statistically unrelated to agreement or disagreement of receptor assays.
format Text
id pubmed-1971742
institution National Center for Biotechnology Information
language English
publishDate 1990
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19717422009-09-10 Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma. Helin, H. Isola, J. Helle, M. Koivula, T. Br J Cancer Research Article Surgical biopsy specimens of 179 breast carcinoma were studied by steroid-binding and immunohistochemical assays or oestrogen and progesterone receptors (ER, PR) in order to explore reasons for discordant results between the two assay types. Receptor statuses in 18% of ER assays and 30% of PR assays were in disagreement. Immunohistochemistry-positive steroid-binding-negative status predominated among the discordant ER assays, while the discordant PR assays displayed the opposite situation. In discordant assays receptor concentration was significantly more often close to the cut-off (10-50 fmol mg-1) than in the concordant ones. Low binding affinity (high Kd) was also significantly associated with disagreeing assay results. These observations clearly indicate that immunohistochemical ER and PR assays measure high-affinity binding components (i.e. type I receptors) in steroid-binding assays. ER but not PR assays in premenopausal women disagreed more often than those in post-menopausal women. Such factors as histological type, specimen size in steroid-binding assay, grade of malignancy and tumour necrosis were statistically unrelated to agreement or disagreement of receptor assays. Nature Publishing Group 1990-07 /pmc/articles/PMC1971742/ /pubmed/2202418 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Helin, H.
Isola, J.
Helle, M.
Koivula, T.
Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma.
title Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma.
title_full Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma.
title_fullStr Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma.
title_full_unstemmed Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma.
title_short Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma.
title_sort discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971742/
https://www.ncbi.nlm.nih.gov/pubmed/2202418
work_keys_str_mv AT helinh discordantresultsbetweenradioligandandimmunohistochemicalassaysforsteroidreceptorsinbreastcarcinoma
AT isolaj discordantresultsbetweenradioligandandimmunohistochemicalassaysforsteroidreceptorsinbreastcarcinoma
AT hellem discordantresultsbetweenradioligandandimmunohistochemicalassaysforsteroidreceptorsinbreastcarcinoma
AT koivulat discordantresultsbetweenradioligandandimmunohistochemicalassaysforsteroidreceptorsinbreastcarcinoma